These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31750897)

  • 41. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
    Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly.
    Lip GY; Lane DA
    Circ J; 2013; 77(6):1380-8. PubMed ID: 23657131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and Associated Stroke Risk of Human Immunodeficiency Virus-Infected Patients With Atrial Fibrillation　- A Nationwide Cohort Study.
    Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B
    Circ J; 2019 Nov; 83(12):2547-2554. PubMed ID: 31619594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study.
    Jung H; Yang PS; Sung JH; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    Thromb Haemost; 2019 Feb; 119(2):285-293. PubMed ID: 30602200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Stroke prevention in atrial fibrillation in Germany. Situational analysis of treatment reality based on retrospective data].
    Mergenthaler U; Kostev K; Moosmang S; Thate-Waschke IM; Haas S
    MMW Fortschr Med; 2017 Dec; 159(Suppl 7):26-32. PubMed ID: 29204949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation.
    Quinn GR; Severdija ON; Chang Y; Singer DE
    Circulation; 2017 Jan; 135(3):208-219. PubMed ID: 27799272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
    Nakamura A; Kuroda J; Ago T; Hata J; Matsuo R; Arakawa S; Kuwashiro T; Yasaka M; Okada Y; Kitazono T; Kamouchi M;
    Cerebrovasc Dis; 2016; 42(3-4):196-204. PubMed ID: 27111222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
    Potpara TS; Lip GY
    Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-Vitamin K Antagonist Oral Anticoagulants in Elderly (≥85 years) Patients With Newly Diagnosed Atrial Fibrillation: Changing Clinical Practice and Outcomes for Stroke Prevention in a Nationwide Cohort Study.
    Cheng WH; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Lip GYH; Chen SA; Chao TF
    Mayo Clin Proc; 2021 Jan; 96(1):52-65. PubMed ID: 33413835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients.
    Chao TF; Liao JN; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Chung FP; Chen TJ; Lip GYH; Chen SA
    Thromb Haemost; 2019 Jul; 119(7):1162-1170. PubMed ID: 30900222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation.
    Chao TF; Lip GYH; Liu CJ; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Chen SA
    J Am Coll Cardiol; 2018 Jan; 71(2):122-132. PubMed ID: 29325634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atrial fibrillation diagnosed after stroke and dementia risk: cohort study of first-ever ischaemic stroke patients aged 65 or older.
    Krawczyk M; Fridman S; Cheng Y; Fang J; Saposnik G; Sposato LA
    Europace; 2019 Dec; 21(12):1793-1801. PubMed ID: 31531673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation.
    Arbel A; Abu-Ful Z; Preis M; Cohen S; Saliba W
    Br J Clin Pharmacol; 2021 Dec; 87(12):4747-4755. PubMed ID: 33982796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib).
    Al-Khatib SM; Pokorney SD; Al-Khalidi HR; Haynes K; Garcia C; Martin D; Goldsack JC; Harkins T; Cocoros NM; Lin ND; Lipowicz H; McCall D; Nair V; Parlett L; McMahill-Walraven CN; Platt R; Granger CB
    Am Heart J; 2020 Nov; 229():110-117. PubMed ID: 32949986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
    Lutsey PL; Norby FL; Zakai NA; MacLehose RF; Chen LY; Shah S; Datta YH; Alonso A
    Curr Med Res Opin; 2019 May; 35(5):837-845. PubMed ID: 30362847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.